Equities Analysts Set Expectations for REVB FY2026 Earnings

Revelation Biosciences, Inc. (NASDAQ:REVB) – Equities researchers at Zacks Research lifted their FY2026 earnings per share (EPS) estimates for shares of Revelation Biosciences in a research report issued to clients and investors on Friday, November 6th. Zacks Research analyst B. Sorensen now expects that the company will earn ($15.08) per share for the year, up from their prior forecast of ($36.18). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($35.08) per share. Zacks Research also issued estimates for Revelation Biosciences’ Q4 2026 earnings at ($5.58) EPS and FY2027 earnings at ($17.78) EPS.

Revelation Biosciences (NASDAQ:REVB) last released its quarterly earnings data on Thursday, November 5th. The company reported ($5.92) earnings per share for the quarter, topping the consensus estimate of ($6.16) by $0.24.

Separately, Weiss Ratings upgraded shares of Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Revelation Biosciences Stock Performance

REVB opened at $4.38 on Friday. Revelation Biosciences has a 52-week low of $3.08 and a 52-week high of $40.60. The stock has a market capitalization of $2.98 million, a PE ratio of -0.10 and a beta of -0.13. The stock’s 50 day moving average price is $5.21 and its 200-day moving average price is $7.47.

About Revelation Biosciences

Revelation Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases. Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.